Vincent P C, Fabre S, Jennis F
Med J Aust. 1977 Oct 8;2(3 Pt 2 Suppl):30-3. doi: 10.5694/j.1326-5377.1977.tb113916.x.
The safety and efficacy of tobramycin, a new aminoglycoside, have been evaluated in combination antibiotic therapy in 49 episodes of infection in 25 neutropenic patients. Tobramycin was used in combination with a cephalosporin in 40 episodes and with carbenicillin in 6. The most common infections were respiratory (21 episodes) and septicaemic (16 episodes). One or more pathogens were identified in 38 episodes, of which 36 were due to Gram-negative organisms. The clinical response was satisfactory in 71% of episodes, and the pathogens were eliminated in 50% of episodes in which follow-up bacteriological investigation was available. No renal, auditory, or vestibular toxicity was observed.
一种新的氨基糖苷类药物妥布霉素在25例中性粒细胞减少患者的49次感染联合抗生素治疗中进行了安全性和有效性评估。妥布霉素在40次治疗中与头孢菌素联合使用，6次与羧苄西林联合使用。最常见的感染是呼吸道感染（21次）和败血症（16次）。38次感染中鉴定出一种或多种病原体，其中36次是由革兰氏阴性菌引起的。71%的治疗临床反应令人满意，在有后续细菌学调查的治疗中，50%的病原体被清除。未观察到肾毒性、耳毒性或前庭毒性。
